Difference between revisions of "NET of unknown primary"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - "==ESMO==" to "==[http://www.esmo.org/ ESMO]==") |
Warner-admin (talk | contribs) m (Text replacement - "==NCCN==" to "==[https://www.nccn.org/ NCCN]==") |
||
| Line 14: | Line 14: | ||
*[http://annonc.oxfordjournals.org/content/26/suppl_5/v133.full.pdf+html Cancers of unknown primary site: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2015)] [https://www.ncbi.nlm.nih.gov/pubmed/26314775 PubMed] | *[http://annonc.oxfordjournals.org/content/26/suppl_5/v133.full.pdf+html Cancers of unknown primary site: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2015)] [https://www.ncbi.nlm.nih.gov/pubmed/26314775 PubMed] | ||
| − | ==NCCN== | + | ==[https://www.nccn.org/ NCCN]== |
*[https://www.nccn.org/professionals/physician_gls/pdf/occult.pdf NCCN Guidelines - Occult Primary (Cancer of Unknown Primary (CUP))] | *[https://www.nccn.org/professionals/physician_gls/pdf/occult.pdf NCCN Guidelines - Occult Primary (Cancer of Unknown Primary (CUP))] | ||
Revision as of 04:43, 16 December 2017
Use of this site is subject to you reading and agreeing with the terms set forth in the disclaimer. If this is your first time visiting, we suggest you read the tutorial.
Is there a regimen missing from this list? Would you like to share a different dosage/schedule or an additional reference for a regimen? Have you noticed an error? Do you have an idea that will help the site grow to better meet your needs and the needs of many others? You are invited to contribute to the site.
0 regimens on this page
0 variants on this page
|
Guidelines
ESMO
- Cancers of unknown primary site: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. (2015) PubMed
NCCN
All lines of therapy
- Poorly differentiated or small cell tumors can be treated with small cell lung cancer regimens.
- Moderate to well-differentiated neuroendocrine tumors can be treated with regimens for neuroendocrine tumors.